Combinatorial ablation and immunotherapy

Replimune to Present at Two Upcoming Investor Conferences

Retrieved on: 
Monday, August 2, 2021
Medical specialties, Clinical medicine, Branches of biology, Oncology, Immune system, Cancer immunotherapy, Vaccines, Cancer, Antigen, Tumor antigen, Treatment of cancer, Combinatorial ablation and immunotherapy

Replimune is developing novel, proprietary therapeutics intended to improve the direct cancer-killing effects of selective virus replication and the potency of the immune response to the tumor antigens released.

Key Points: 
  • Replimune is developing novel, proprietary therapeutics intended to improve the direct cancer-killing effects of selective virus replication and the potency of the immune response to the tumor antigens released.
  • Replimunes Immulytic platform is designed to maximize systemic immune activation, in particular to tumor neoantigens, through robust viral-mediated immunogenic tumor cell killing and the delivery of optimal combinations of immune-activating proteins to the tumor and draining lymph nodes.
  • The approach is expected to be highly synergistic with immune checkpoint blockade and other approaches to cancer treatment across a broad range of cancers.
  • Replimune intends to progress these therapies rapidly through clinical development in combination with other immuno-oncology products with complementary mechanisms of action as well as in standalone indications.For more information, please visit www.replimune.com .

NexImmune to Present at the Raymond James 2021 Human Health Innovation Conference

Retrieved on: 
Wednesday, June 16, 2021
Medical specialties, Clinical medicine, Medicine, Cancer immunotherapy, Immunotherapy, Virotherapy, Dendritic cell, Immune system, Dendritic cell-based cancer vaccine, Combinatorial ablation and immunotherapy

The presentation will be accessible via live webcast by visiting https://ir.neximmune.com/investors/events-and-presentations .

Key Points: 
  • The presentation will be accessible via live webcast by visiting https://ir.neximmune.com/investors/events-and-presentations .
  • A replay will be available on the NexImmune website following the presentation.
  • NexImmune is a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the bodys own T cells to generate a specific, potent, and durable immune response.
  • The AIM technology enables NexImmune to construct nanoparticles that function as synthetic dendritic cells capable of directing a specific T cell-mediated immune response.

Intensity Therapeutics Reports Favorable Data of INT230-6 from the Ongoing Phase 1/2 Study (IT-01/KEYNOTE A10) in Patients with Advanced Solid Tumors at SITC 2020 (Abstract 411)

Retrieved on: 
Wednesday, November 11, 2020
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Clinical medicine, Medicine, Medical specialties, Immunotherapy, Oncology, Combinatorial ablation and immunotherapy, Pelareorep, INT230-6, Intensity Therapeutics

The emerging data shows that the treatment is well tolerated with no patients having to discontinue therapy due to treatment-related toxicities.

Key Points: 
  • The emerging data shows that the treatment is well tolerated with no patients having to discontinue therapy due to treatment-related toxicities.
  • The presentation includes survival analysis on heavily pretreated patients with 19 different types of advanced or metastatic solid tumors.
  • INT230-6 is currently being evaluated in Phase 2 clinical studies ( NCT03058289 ) in patients with various advanced solid tumors.
  • Intensity Therapeutics, Inc. is a privately held, clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers.

Tumor Ablation Market Worth $ 1072.87 Million, Globally, by 2027 at 12.1% CAGR: Verified Market Research

Retrieved on: 
Thursday, November 5, 2020
Medical specialties, Medicine, Clinical medicine, Interventional radiology, Microwave ablation, Cryoablation, Ablation, Bone metastasis, Liver cancer, Radiofrequency ablation, Combinatorial ablation and immunotherapy

JERSEY CITY, N.J., Nov. 5, 2020 /PRNewswire/ -- Verified Market Research recently published a report, " Tumor Ablation Market by Technology (Microwave Ablation, Radiofrequency (RF) Ablation, Cryoablation), by Mode of Treatment (Laparoscopic Ablation, Surgical Ablation, Percutaneous Ablation), by Application (Lung Cancer, Liver Cancer, Kidney Cancer, Bone Metastasis), Geography".

Key Points: 
  • JERSEY CITY, N.J., Nov. 5, 2020 /PRNewswire/ -- Verified Market Research recently published a report, " Tumor Ablation Market by Technology (Microwave Ablation, Radiofrequency (RF) Ablation, Cryoablation), by Mode of Treatment (Laparoscopic Ablation, Surgical Ablation, Percutaneous Ablation), by Application (Lung Cancer, Liver Cancer, Kidney Cancer, Bone Metastasis), Geography".
  • According to Verified Market Research, the Global Tumor Ablation Market was valued at USD 458.30 Million in 2019 and is projected to reach USD 1072.87 Million by 2027, growing at a CAGR of 12.1% from 2020 to 2027.
  • Technological advancements in tumor ablation devices on the basis of accuracy, cost effectiveness, and portability and growing number of cancer patients are the factors fueling the growth of global tumor ablation market.
  • Verified Market Research has segmented the Global Tumor Ablation Market on the basis of Technology, Mode of Treatment, Application and Geography.

Cue Biopharma Announces Nature Methods Publication of Preclinical Data Showing Tumor Penetration and Antigen-Specific T Cell Engagement with Immuno-STAT Based Protein Scaffolds

Retrieved on: 
Tuesday, September 15, 2020
Medical specialties, Clinical medicine, Medicine, Oncology, Immune system, Tumor antigen, Antigen, Immunotherapy, Combinatorial ablation and immunotherapy, Tumor antigen vaccine

In this work, researchers employed dimeric protein scaffolds to develop a novel immuno-positron emission tomography (immunoPET) imaging approach.

Key Points: 
  • In this work, researchers employed dimeric protein scaffolds to develop a novel immuno-positron emission tomography (immunoPET) imaging approach.
  • By targeting synTacs labelled with positron emitting isotopes against specified tumor antigens, researchers were able to specifically and non-invasively detect tumor antigen-specific T cells in murine solid tumor models.
  • In the same study, similar application of synTacs deploying viral antigens could detect and engage virus-specific T cells in the lung tissue.
  • Data showing the efficient penetration of the HPV16 E7 targeted synTac into solid tumors are particularly noteworthy, as similar technologies are unable to deliver cargoes past the tumor periphery.

Acutus Medical Announces Pulse Field Ablation Program and Initial Pre-Clinical Results

Retrieved on: 
Tuesday, September 8, 2020
Medicine, Branches of biology, Clinical medicine, Interventional radiology, Plasma physics, Ablation, Cryoablation, Electroporation, Combinatorial ablation and immunotherapy, Microwave ablation

CARLSBAD, Calif., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (NASDAQ:AFIB) today announced pre-clinical experimental results of a novel diagnostic and therapeutic workflow utilizing the AcQMap System along with tissue-selective, non-thermal pulse field ablation (PFA) via a proprietary Acutus ablation catheter.

Key Points: 
  • CARLSBAD, Calif., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (NASDAQ:AFIB) today announced pre-clinical experimental results of a novel diagnostic and therapeutic workflow utilizing the AcQMap System along with tissue-selective, non-thermal pulse field ablation (PFA) via a proprietary Acutus ablation catheter.
  • Pulsed field ablation (also known as electroporation) is an emerging ablation modality that distinguishes itself from traditional thermal ablation, such as radiofrequency energy ablation and cryoablation, by delivering therapeutic energy faster and more selectively with minimal collateral damage.
  • The application time required to create a lesion takes less than a second compared to thermal ablation which may take many seconds to minutes at each location.
  • Acutus has consistently been focused on challenging industry standards, thinking outside of the box and investing in highly novel technologies.

Innovative Cellular Therapeutics Announces Details of Two Abstracts on its Novel CoupledCAR® Solid Tumor CAR-T Technology to be Presented Orally at the 23rd American Society of Gene & Cell Therapy Meeting

Retrieved on: 
Wednesday, April 29, 2020
Medicine, Branches of biology, Clinical medicine, Cancer treatments, Chimeric antigen receptor T cell, Gene therapy, Immune system, Lymphoma, Tumor microenvironment, E-selectin, Combinatorial ablation and immunotherapy, Tumor-infiltrating lymphocytes

The abstracts have been selected for oral presentation on May 15, 2020, at the 23rd American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, which will be conducted virtually.

Key Points: 
  • The abstracts have been selected for oral presentation on May 15, 2020, at the 23rd American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, which will be conducted virtually.
  • CoupledCAR is ICTs novel, in-house developed, proprietary CAR-T platform technology designed to overcome the challenges observed with conventional CAR-T therapies in treating solid tumors.
  • CoupledCAR significantly improves the expansion of CAR-T cells in vivo and enhances the CAR-T cells migration ability and resistance to immunosuppression in the tumor microenvironment.
  • This allows the CoupledCAR CAR-T cells to infiltrate tumor tissue sites and increase anti-tumor activities, said Larry (Lei) Xiao, Ph.D., ICTs Founder and Chief Executive Officer.

The Global Tissue Ablation Market is expected to grow from USD 13,823.13 Million in 2018 to USD 22,452.13 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 7.17%

Retrieved on: 
Wednesday, April 15, 2020
Medicine, Interventional radiology, Medical specialties, Clinical medicine, Radiofrequency ablation, Ablation, Microwave ablation, Cryoablation, Combinatorial ablation and immunotherapy

On the basis of Type, the Global Tissue Ablation Market is studied across Cardiology, Cosmetology, Gynecology, Oncology, Ophthalmology, and Urology.

Key Points: 
  • On the basis of Type, the Global Tissue Ablation Market is studied across Cardiology, Cosmetology, Gynecology, Oncology, Ophthalmology, and Urology.
  • On the basis of Application, the Global Tissue Ablation Market is studied across Cryoablation Devices, EBRT, Hydrothermal Ablation, Laser-Based Ablation, Microwave Ablation, Radiofrequency Ablation, and Ultrasound Ablation.
  • What are the factors that affect the growth in the Global Tissue Ablation Market over the forecast period?
  • Which are the best product areas to be invested in over the forecast period in the Global Tissue Ablation Market?

Tumor Ablation Market Size Worth $2.6 Billion by 2027 | CAGR: 11.2 %: Grand View Research, Inc.

Retrieved on: 
Monday, February 17, 2020
Medicine, Medical specialties, Interventional radiology, Clinical medicine, Ablation, Magnetic resonance imaging, Surgical oncology, Oncology, Combinatorial ablation and immunotherapy, Radiofrequency ablation

SAN FRANCISCO, Feb. 17, 2020 /PRNewswire/ -- The global tumor ablation market size is anticipated to reach USD 2.6 billion by 2027, according to a new report by Grand View Research, Inc.

Key Points: 
  • SAN FRANCISCO, Feb. 17, 2020 /PRNewswire/ -- The global tumor ablation market size is anticipated to reach USD 2.6 billion by 2027, according to a new report by Grand View Research, Inc.
  • Increasing incidence of cancer and high demand for effective treatment options are the major factors driving the market.
  • Integration of tumor ablation devices with efficient interventional imaging modalities such as ultrasound, MRI, and CT is anticipated to revolutionize ablation procedures performed in outpatient settings.
  • Grand View Research has segmented the global tumor ablation market on the basis of technology, treatment, application, and region:
    Tumor Ablation Technology Outlook (Volume, '000 Units; Revenue, USD Million, 2016 - 2027)

Tumor Ablation Market Size Worth $2.6 Billion by 2027 | CAGR: 11.2 %: Grand View Research, Inc.

Retrieved on: 
Monday, February 17, 2020
Medicine, Medical specialties, Interventional radiology, Clinical medicine, Ablation, Magnetic resonance imaging, Surgical oncology, Oncology, Combinatorial ablation and immunotherapy, Radiofrequency ablation

SAN FRANCISCO, Feb. 17, 2020 /PRNewswire/ -- The global tumor ablation market size is anticipated to reach USD 2.6 billion by 2027, according to a new report by Grand View Research, Inc.

Key Points: 
  • SAN FRANCISCO, Feb. 17, 2020 /PRNewswire/ -- The global tumor ablation market size is anticipated to reach USD 2.6 billion by 2027, according to a new report by Grand View Research, Inc.
  • Increasing incidence of cancer and high demand for effective treatment options are the major factors driving the market.
  • Integration of tumor ablation devices with efficient interventional imaging modalities such as ultrasound, MRI, and CT is anticipated to revolutionize ablation procedures performed in outpatient settings.
  • Grand View Research has segmented the global tumor ablation market on the basis of technology, treatment, application, and region:
    Tumor Ablation Technology Outlook (Volume, '000 Units; Revenue, USD Million, 2016 - 2027)